CJC-1295 (No DAC) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), developed for research into growth hormone regulation, metabolism, and physiological performance. Unlike the DAC-modified version, CJC-1295 (No DAC) has a shorter half-life, allowing for more controlled and pulsatile stimulation of growth hormone release in experimental settings. This peptide is widely studied for its potential to increase natural growth hormone and insulin-like growth factor-1 (IGF-1) levels, which may influence metabolic activity, body composition, and cellular recovery processes. Its mechanism of action closely mimics the body’s natural hormone release patterns, making it a valuable compound in research focused on endocrine function. CJC-1295 (No DAC) is also of interest in studies related to fat metabolism, recovery, and overall physiological optimization. Its short-acting nature provides flexibility in experimental protocols and timing of administration.